Suven Pharmaceuticals Limited, a active public limited company, was established on 06 November 2018 in Hyderabad, Telangana, India. Engaging in pharmaceutical formulations within the manufacturing sector, it holds CIN: U24299TG2018PLC128171. Registered under ROC Roc-Hyderabad. it is listed on BSE: 543064 and NSE: SUVENPHAR. It has an authorized capital of ₹40.00 Cr and a paid-up capital of ₹25.46 Cr.
In 2022, it reported revenue of ₹1,508.01 Cr and a net worth of ₹1,520.69 Cr. Employing 943 professional, Its leadership includes Jerry Jeyasingh (Director). Past directors included Venkateswarlu Jasti. It holds ₹174.02 Cr open charges and no settled loans. Its latest AGM occurred on 31 August 2021, with the balance sheet filed on 31 March 2021. It is based at # 8-2-334, Sde Serene Chambers, 3Rd Floor, Avenue 7, Road No. 5, Banjara Hills, Hyderabad, Telangana, 500034.
U24299TG2018PLC128171
128171
06 November 2018
₹40.00 Cr
₹25.46 Cr
Roc-Hyderabad
Listed (BSE: 543064, NSE: SUVENPHAR)
Active
Explore comprehensive insights into Suven Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jerry Jeyasingh | Director | 06 Nov 2019 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Chief Executive Officer | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Suven Pharmaceuticals Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 47.27% increase. The company also saw a substantial improvement in profitability, with a 80.82% increase in profit. The company's net worth Soared by an impressive increase of 42.76%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2021, Suven Pharmaceuticals had a promoter holding of 60.00% and a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹1,740,200,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Dec 2020 | Bank Of Bahrain And Kuwait Bsc | ₹10.00 Cr | Open |
| 05 Nov 2020 | State Bank Of India | ₹164.02 Cr | Open |
Explore comprehensive loan charge details -
Suven Pharmaceuticals has a workforce of 877 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Suven Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suven Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Suven Pharmaceuticals Limited last Annual general meeting of members was held on 31 Aug 2021 as per latest MCA records. was completed.
Progress on Suven Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2021 with RoC-Hyderabad. was documented.
The activity A charge with Bank Of Bahrain And Kuwait Bsc amounted to Rs. 10.00 Cr with Charge ID 100402459 was registered on 29 Dec 2020. was completed.
The activity A charge with State Bank Of India of Rs. 164.02 Cr registered on 05 Nov 2020 with Charge ID 100391471 was modified on 28 Dec 2020. was completed.
A charge with State Bank Of India amounted to Rs. 164.02 Cr with Charge ID 100391471 was registered on 05 Nov 2020. was recorded as a recent event.
Progress on Hanumantha Rao Kokkonda was appointed as a Company Secretary was appointed as a Company Secretary on 10 Jan 2020 & has been associated with this company since 5 years 10 months . was documented.
The CIN of Suven Pharmaceuticals Limited is U24299TG2018PLC128171.
Suven Pharmaceuticals Limited is headquartered at # 8-2-334, Sde Serene Chambers, 3Rd Floor, Avenue 7, Road No. 5, Banjara Hills, Hyderabad, Telangana, 500034.
Suven Pharmaceuticals Limited was incorporated on 06 November 2018.
The current directors of Suven Pharmaceuticals Limited are
The primary industry of Suven Pharmaceuticals Limited is Manufacturing.
Suven Pharmaceuticals Limited is listed. It is listed on BSE: 543064 and NSE: SUVENPHAR.
The authorized capital of Suven Pharmaceuticals Limited is ₹40.00 Cr, and the paid-up capital is ₹25.46 Cr.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX